We have located links that may give you full text access.
Treatment outcome in juvenile-onset myasthenia gravis.
Muscle & Nerve 2019 May
INTRODUCTION: Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction. Approximately 10%-15% of MG patients have juvenile (<18 years of age) onset. We aimed to assess the clinical course, outcome, and subjectively perceived health status of a cohort of juvenile MG patients.
METHODS: This was a retrospective analysis of medical records of 101 patients followed by a cross-sectional questionnaire study.
RESULTS: The mean age of patients was 12.8 years at onset and 13.7 years at diagnosis. Ninety percent of the patients were seropositive. Over 40% of the patients were treated with immunosuppression and over 80% underwent thymectomy. The mean Myathenia Gravis Activities of Daily Living (MG-ADL) scale score was 2.48. At last follow-up, 30.9% of patients were in complete, stable remission; 77.8% perceived their health as good.
DISCUSSION: The treatment outcome for juvenile MG is favorable, with a marked reduction of symptoms and good day-to-day activity achieved for most patients. Muscle Nerve 59:549-549, 2019.
METHODS: This was a retrospective analysis of medical records of 101 patients followed by a cross-sectional questionnaire study.
RESULTS: The mean age of patients was 12.8 years at onset and 13.7 years at diagnosis. Ninety percent of the patients were seropositive. Over 40% of the patients were treated with immunosuppression and over 80% underwent thymectomy. The mean Myathenia Gravis Activities of Daily Living (MG-ADL) scale score was 2.48. At last follow-up, 30.9% of patients were in complete, stable remission; 77.8% perceived their health as good.
DISCUSSION: The treatment outcome for juvenile MG is favorable, with a marked reduction of symptoms and good day-to-day activity achieved for most patients. Muscle Nerve 59:549-549, 2019.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app